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Abstract
Background: Various patient reported quality-of-life indicators are independently prognostic for survival in
metastatic breast cancer and other cancers. The same measures recorded at first diagnosis of early breast
cancer carry no corresponding prognostic information. The present study aims to assess at what time in the
disease evolution the prognostic association appears.
Methods: Among 8024 patients enrolled in one of seven randomized controlled trials in early-stage breast
cancer 3247 had a breast cancer relapse after a median follow-up of 12.1 years. Of these 677 had
completed QL indicator assessments within defined windows 1, 2 or 3 months prior to relapse. We
performed Cox regression analyses using these assessments and using identical instruments after relapse.
All analyses were stratified by trial and adjusted for baseline clinicopathologic factors.
Results: QL indicators in the months before relapse were not significantly prognostic for subsequent
survival with the possibly chance exception of mood at the second month before relapse. After relapse,
physical well-being was statistically significantly associated with survival (P < 0.001). This prognostic
significance increased in later post-relapse assessments. Similar findings were observed using patient-
reported indicators for nausea and vomiting, appetite, coping effort, and health perception.
Conclusions: Before cancer relapse, QL indicators were not generally prognostic for subsequent survival.
After relapse, QL indicators substantially predicted OS, with a stronger association later in the course of
relapsed disease. Simple patient perception of disease burden seems unlikely to explain this sudden
change: rather the patient’s awareness of disease relapse must contribute.
Keywords: Breast cancer, Quality of life, Patient reported outcomes, Linear analog self-assessment,
Prognostic factors, Survival
Background
Previous studies have shown that various patient-
reported quality-of-life (QL) indicators independently
predict survival outcomes in metastatic breast cancer
[1–5] and other cancer types [5–8]. By contrast, in
studies of early-stage breast cancer, no clear relation-
ship between QL indicators and survival has been
reported [9–11], though small studies have reported
associations with appetite loss [12], future perspective
[13], social wellbeing [14] and with physical and func-
tional impairment [15], while a decrease in depression
was reported to be associated with longer survival
[16]. The reason for this discrepancy is uncertain. If
the prognostic associations in advanced disease reflect
patients’ perceptions of underlying disease severity, it
may well be that at initial diagnosis of early-stage dis-
ease there are no such symptoms to perceive. The
timing of the emergence of prognostic association of* Correspondence: alan.coates@ctc.usyd.edu.au
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patient-reported QL indicators is therefore important
because it might illuminate the mechanism for the
association of such indicators with subsequent sur-
vival. The present study uses available individual-
patient data from seven International Breast Cancer
Study Group (IBCSG) adjuvant therapy trials that in-
cluded QL assessments. We hypothesized that there
may be a lead time prior to cancer relapse during QL
indicators were prognostic for subsequent survival
duration. Our primary objective was to examine the
association between survival and QL indicators re-
corded at time points shortly before each patient’s
date of disease relapse, and as a secondary aim to
document the time course of the prognostic signifi-
cance of the same QL indicators recorded at various
intervals after relapse.
Patients and methods
Between 1986 and 2000, seven IBCSG trials rando-
mised a total of 8024 women with operable breast
cancer to different systemic treatment comparisons.
Trial VI randomised premenopausal women with
node-positive cancer and investigated the optimal
duration and timing of adjuvant chemotherapy [17].
Trial VII [18] and trial IX [19] investigated the value
of adding chemotherapy to tamoxifen to treatment
for postmenopausal women with node-positive and
node-negative tumors, respectively. Trial VIII investi-
gated the role of treatment with chemotherapy, endo-
crine therapy comprising ovarian suppression with
goserelin, and the sequential use of these modalities
in premenopausal and perimenopausal women with
node-negative tumors [20]. Trial 13–93 examined the
introduction of a treatment gap and the value of
adding tamoxifen to chemotherapy in premenopausal
women [21], while Trial 14–93 investigated the role
of a treatment-free gap in postmenopausal women
[22]. Trial 15–95 investigated dose-intensive chemo-
therapy in women with high-risk, node-positive breast
cancer [23].
In all of these trials, QL was measured using vali-
dated single-item linear analog self-assessment (LASA)
indicators of components of QL (physical wellbeing,
mood, coping, and perceived health status) shown to
be affected by breast cancer, surgery, chemo- and
endocrine therapy [24–27]. These were global indica-
tors for physical well-being, mood, coping effort and
perceived health status (utility). The specific indicators
for side-effects were nausea/vomiting, appetite, flush-
ing, and arm restriction. Mood and coping indicators
are shown to be sensitive in identifying psychological
distress, mood disorders and psychosocial dysfunction.
The clinical relevance of global and specific LASA in-
dicators has been confirmed in breast cancer trials
that examined the impact of axillary clearance,
chemo- and endocrine therapy, and by their association
with performance status, tumor response, chemotherapy
treatment benefit and toxicity, and survival duration.
Each LASA indicator consisted of a 100-mm line, with
scores ranged from 0 (best) to 100 (worst). The schedule
of QL assessments was essentially similar in all trials,
with regular early measures then additional assessment
following relapse.
Statistical methods
Only patients with documented breast cancer relapse
were considered. In these patients, we examined the
relationship of each QL indicator with OS using Cox
regression models. All our models were stratified by
trial enrolment. The hazard ratio (HR) was calculated
using the estimated parameter from these models and
represents the risk for a 1 point increase of the 100
point QL scale (that is, as the QL indicator worsens,
the HR increases).
Our primary analysis sought any association be-
tween QL indicators and subsequent OS before can-
cer relapse. Survival times were measured from the
landmark times before cancer relapse to the date of
death (from any cause) or date of last follow-up.
Three arbitrary time periods were chosen: 1, 2, and
3 months before the date of each patient’s docu-
mented relapse. QL indicators recorded within a win-
dow of 2 weeks around each of these times were
analysed. In our primary analysis, all types of breast
cancer relapses were considered. Multivariable ana-
lyses were performed to adjust for baseline factors at
initial diagnosis (age, tumor size, estrogen receptor,
performance status and axillary nodal status (node-
negative vs 1–3 positive nodes vs 1–3 v 4or more
positive nodes). We further performed a sensitivity
analysis in which only cases with distant metastasis
to skeletal, viscera, distant nodes and / or soft tissues
were examined.
In our secondary analysis, we examined for the as-
sociation between QL indicators at and after cancer
relapse and subsequent survival. Survival times were
measured from the dates of the first, second, and
third QL indicator readings after relapse to the date
of death (from any cause) or the date of last follow-
up. The relationships between 1st, 2nd, and 3rd
post-relapse QL indicators and survival from the
time of relapse were tested singly using univariable
Cox regression analyses stratified by trial. Multivari-
able analyses jointly explored first and second, and
first, second, and third post-relapse QL indicators. In
these multivariable analyses, survival times were
measured (landmarked) from the dates of the latest
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QL indicator readings after relapse to the date of
death. There was no adjustment for multiple com-
parisons. All analyses were two sided, and P < 0.05
was considered significant.
Results
Of a total of 8024 patients, 3834 (47.8%) had a
protocol-defined DFS event (first occurrence of
breast cancer recurrence at local, regional, or distant
site, contralateral breast cancer, second malignancy
or death prior to a cancer event) during a median
follow-up period of 12.1 years (range 0 to 21.5 years)..
The patient and disease characteristics at trial entry,
and QL data availability, are summarized in Table 1.
Because we wanted to focus only on breast cancer
relapse, we excluded 346 patients with a non-breast
second primary malignancy, 223 who died without
disease recurrence and 18 the nature of whose DFS
event was unknown, leaving 3247 who had disease
relapse in the main analytic cohort. Of these, 1243
(38%) had a relapse involving local or regional sites
or contralateral breast and the remaining 2004 (62%)
distant metastatic disease (Table 4 in Appendix 3).
Prognostic relevance of QL indicators measured before
cancer relapse
Since the date of relapse could not be known pro-
spectively, available QL forms in arbitrary 2-week
time windows 1, 2 and 3 months prior to each
patient’s data of relapse were used. Amongst 3247
patients who had disease relapse, QL forms were
completed by 677 (20.9%) in one of these windows:
no patient had data in more than one window
(Table 1). Table 2 in Appendix 1 summarizes the
distribution of QL indicators at different landmark
times before and after breast cancer relapse. Table 3
in Appendix 2 shows the distribution of the different
sites / types of breast cancer relapse and other DFS
events.
At 1 month and 3 months before disease relapse,
none of the QL indicators showed a statistically
Table 1 Patient and disease characteristics at trial entry, and quality of life data availability, in those with breast cancer related
relapse
Overall Trial VI Trial VII Trial VIII Trial IX Trial 13 Trial 14 Trial 15
Patients enrolled 8024 1475 1212 1109 1669 1246 969 344
Patients who relapsed (analytic cohort) 3247 848 656 281 339 511 417 195
Characteristics in analytic cohort
Age, median 50 44 60 44 61 43 58 46
Range 23–79 24–57 38–79 29–56 34–76 23–57 40–70 25–65
Menopausal, n (%) 1475 (45.4) 0 (0) 656 (100) 2 (0.7) 339 (100) 4 (0.8) 413 (99.0) 61 (31.3)
Tumor >2 cm, n (%) 1998 (62.8) 523 (63.2) 4 s24 (65.3) 120 (43.2) 182 (53.9) 338 (68.2) 270 (67.3) 141 (72.7)
1–3 involved axillary lymph nodes, n (%) 1189 (36.6) 454 (53.5) 338 (51.5) 0 (0) 1 (0.3) 250 (48.9) 146 (35.0) 0 (0)
≥ 4 involved axillary lymph nodes, n (%) 1438 (44.3) 394 (46.5) 318 (48.5) 0 (0) 0 (0) 261 (51.1) 270 (64.8) 195 (100)
Estrogen receptor positive, n (%) 2154 (66.5) 585 (69.0) 485 (73.9) 211 (75.4) 256 (76.7) 297 (58.1) 245 (58.8) 75 (38.7)
Mastectomy, n (%) 2258 (69.5) 637 (75.1) 543 (82.8) 130 (46.3) 182 (53.7) 327 (64.0) 291 (69.8) 148 (75.9)
Radiotherapy, n (%) 979 (30.2) 201 (23.7) 106 (16.2) 121 (43.1) 128 (37.8) 184 (36.0) 128 (30.7) 111 (56.9)
QL data availability at 1, 2 or 3 months
before relapsea, n (%)
677 (20.9) 187 (22.1) 130 (19.8) 59 (21.0) 50 (14.7) 106 (20.7) 91 (21.8) 54 (27.7)
1 month 199 39 34 17 15 36 31 27
2 months 163 40 30 16 10 30 27 10
3 months 315 108 66 26 25 40 33 17
QL data availability at or after relapseb,
n (%)
1309 (40.3) 354 (41.7) 262 (39.9) 96 (34.2) 102 (30.1) 233 (45.6) 170 (40.8) 92 (47.2)
First post-relapse reading 1309 354 262 96 102 233 170 92
Second post-relapse reading 661 188 135 57 45 125 70 41
Third post-relapse reading 202 25 25 29 22 57 31 13
QL quality of life
aat each time point before relapse, patients did not complete more than one QL assessments
bat each time point after relapse, patients could complete one or more QL (non-protocol) assessments
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significant relationship with subsequent OS. The re-
sults did not change significantly with adjustment for
baseline factors. At 2 months before disease relapse,
none of the QL indicators, except mood (HR for a 1-
point change 1.008, 95% confidence interval (CI)
1.001 to 1.015, uncorrected P = 0.03), showed a statis-
tically significant relationship with OS. We regard this
association with mood at a single time point as a
statistical artefact without biological significance.
When adjusted for baseline prognostic factors, none
of the QL indicators, including mood, were associated
with survival (Fig. 1).
Prognostic relevance of QL indicators measured at and
beyond cancer relapse
The median survival time after disease relapse was
2.5 years (range 0 to 19.7 years). At or after disease
relapse, QL forms were completed at least once by
1309 patients (40.3%) in the study cohort (Table 1).
With a median time of 1.2 months after cancer relapse
(first post-relapse QL indicators), physical well-being
(HR per 1-point change 1.006, 95% CI 1.004 to 1.008,
P < 0.001), was statistically significantly associated
with OS. At the second post-relapse (median time
6.8 months), the corresponding HR was 1.008 (95%
CI 1.005 to 1.011, P < 0.001) and at the third post-
relapse (median time 17.8 months), 1.013 (95% CI
1.07 to 1.018, P < 0.001). QL indicators for nausea
and vomiting, appetite, coping effort and utility taken
at these time-points after cancer relapse also showed
patterns similar to those for physical well-being
(Fig. 2).
When the second post-relapse QL indicators for
physical well-being was adjusted for the first post-
relapse QL indicators in a multivariable model, the
HR for the second post-relapse QL indicators was
1.008 (95% CI 1.005 to 1.011, P < 0.001) while the
first post-relapse QL indicators was no longer statisti-
cally significant (P = 0.85). The same pattern was ob-
served among the small group who reported third
post-relapse QL indicators adjusted for first and sec-
ond post-relapse scores in a multivariable model
(Fig. 3). These results imply that the physical well-
being measured later in the evolution of recurrent
disease has a stronger association with OS than earl-
ier measurements. Similar results were observed for
nausea and vomiting, appetite, coping effort, and utility
(results not shown).
Discussion
Interest in the psychological correlates of prognosis
in cancer has been longstanding. Our own studies in
metastatic breast cancer [28] and melanoma [29]
found a consistent positive effect of “minimization” of
concern. In this study, using established QL indica-
tors which had proven prognostic in metastatic dis-
ease [2, 9] we could not demonstrate any lead-time
effect, in that none of the QL indicators, (apart from
the possibly chance finding of mood at 2 months),
measured at 1, 2, and 3 months before cancer relapse
had prognostic significance for subsequent survival.
By contrast, and in keeping with prior observations,
the same indicators recorded at and after cancer re-
lapse substantially predicted subsequent survival,
with stronger association for QL indicators measured
later in the course of relapsed disease. The hazard
ratios observed after relapse represent large effect
size: every 10 points worsening of physical well-
being, at the median time of 1.3 months after pro-
gression, was associated with 7% increase in hazard
of death. At median times of 5.8 and 10.1 months
after progression, the corresponding hazards of death
were increased to 8% and 13%, respectively for every
10 points worsening of physical well-being.
This study has several strengths. It is based on in-
dividual patient QL indicator data prospectively col-
lected in almost 4000 patients from seven adjuvant
clinical trials. Among these, 22.9% had available QL
indicator data falling in the period prior to the time
of relapse and 40.3% had QL indicator data soon
thereafter, enabling prognostic analyses to be per-
formed at various stages of the disease trajectory
around the event of disease relapse.
There are also several limitations of this study. The
findings remain hypothesis-generating, as none of
these clinical trials were originally designed to answer
the research questions addressed in this paper. Pa-
tients were classified in these trials as having disease
progression if they had local recurrence and / or more
distant metastatic disease. Patient’s self-perception of
the severity of the disease might differ between those
who developed a local recurrence versus those with
distant metastasis and hence might potentially impact
on the results. However, our sensitivity analysis (Table 4
in Appendix 3) does not suggest major differences in
the result of all types of relapse versus those with
distant metastases only. For feasibility reasons, in
these large-scale phase-III international studies where
trials were conducted in different cultures with diffe-
rent local settings and resources, key indicators rele-
vant to patients with breast cancer were selected as
an alternative to a comprehensive QL assessment
[24, 25]. Because the time of relapse could not be
prospectively known, QL indicator data were only
available from 22.9% of patients at the chosen time
points 1, 2 or 3 months before relapse. Moreover,
these data were generally from patients who relapsed
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early during or immediately after completion of ad-
juvant systemic treatments (when QL indicator
assessments were scheduled) rather than those who
relapsed later. We do not have detailed clinicopatho-
logic information about the sites of relapse in these
patients and have therefore not attempted to
A
B
C
Fig. 1 Unadjusted and adjusted hazard ratios for overall survival for 1 point scale worsening of each quality-of-life (QL) indicator at (A)
1 month, (B) 2 months, and (C) 3 months before breast cancer relapse. Hazard ratios for each QL indicators are represented by the
squares, and the horizontal line crossing the square represents the 95% confidence interval
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separately assess the prognostic relevance of QL
indicators after relapse at various different sites. Our
multivariable analyses only adjusted for baseline fac-
tors at diagnosis of early-stage breast cancer. Thus,
it is possible that QL indicator data might not be
prognostic for survival after relapses confined, say,
to soft tissues. We used QL indicators at various
time points but did not examine for effects of
change in the score. However, changes in QL indica-
tor from baseline (at the commencement of adjuvant
therapy) to before and during cancer relapse may be
difficult to interpret because of the significant time
gap for most of these patients, and the phenomenon
of response shift [30–32].
Conclusion
In conclusion, QL indicators measured at various in-
tervals before cancer relapse did not have prognostic
significance for subsequent OS. At and after cancer
relapse, QL indicators substantially predicted subse-
quent OS, with stronger association for QL indica-
tors measured in the later course of relapsed disease.
Patients’ self-perception of the severity of the under-
lying disease after relapse might be a reason for the
reported QL indicators and thus contributes to their
prognostic significance.
Fig. 2 Unadjusted and adjusted hazard ratios for overall survival for
1 point scale worsening of each quality-of-life (QL) indicator after
cancer relapse. PWB = physical well-being; NV = nausea and vomiting
Superior Survival                Inferior Survival
0.990 0.995 1.000 1.005 1.010 1.015 1.020
N
2nd post-relapse reading
1st post-relapse reading
650
650
3rd post-relapse reading
2nd post-relapse reading
1st post-relapse reading
192
192
192
Multivariate Adjustment of 2nd post-relapse reading
Multivariate Adjustment of 3rd post-relapse reading
A
B
Fig. 3 Hazard ratios for overall survival for 1 point scale worsening of physical well-being assessment when (a) the second post-relapse score for
physical well-being was adjusted for the first post-relapse score, and (b) the third post-relapse score for physical well-being was adjusted for the
first and second post-relapse score
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Appendix 1
Appendix 2
Table 2 Distribution of quality-of-life indicators at different landmark times before and after breast cancer relapse
1 month prior relapse 2 months prior relapse 3 months prior relapse
QL Indicators N Mediana IQR N Mediana IQR N Mediana IQR
Physical well-being 199 14.0 29.0 163 20.0 39.0 315 16.0 32.0
Mood 199 20.0 40.0 162 16.0 41.0 315 17.0 39.0
Nausea / Vomiting 140 3.0 7.0 90 3.0 7.0 143 3.0 13.0
Appetite 199 8.0 19.0 163 7.0 19.0 313 7.0 18.0
Flushing 139 22.0 58.0 90 27.0 70.0 144 17.5 62.0
Arm swelling 139 11.0 28.0 89 11.0 31.0 144 13.0 34.5
Coping 198 20.0 44.0 162 21.0 43.0 309 20.0 36.0
Utility 138 21.0 28.0 89 23.0 34.0 142 19.0 33.0
1st reading post-relapse 2nd reading post-relapse 3rd reading post-relapse
QL Indicators N Median IQR N Median IQR N Median IQR
Physical well-being 1309 26.0 46.0 650 24.0 45.0 198 27.0 45.0
Mood 1303 27.0 46.0 645 23.0 42.0 198 22.5 41.0
Nausea / Vomiting 840 3.0 14.0 401 4.0 15.0 153 2.0 7.0
Appetite 1303 9.0 32.0 648 10.0 37.5 199 11.0 34.0
Flushing 838 19.5 49.0 398 18.0 51.0 153 23.0 54.0
Arm swelling 834 11.0 36.0 398 13.0 41.0 154 13.0 41.0
Coping 1298 35.0 50.0 646 32.0 50.0 196 31.0 53.0
Utility 819 31.0 39.0 396 33.0 35.5 152 33.0 39.0
QL quality of life, IQR interquartile range
aEach linear analog self-assessment QL indicators consisted of a 100-mm line, with scores ranged from 0 (best) to 100 (worst)
Table 3 Number of patients with different types of breast cancer relapses for each trial
Trial Number VI VII VIII IX 13 14 15 Total
N
No relapse 568 380 789 1118 704 495 136 4190
Local recurrence 167 102 88 84 92 72 20 625
Contralateral breast cancer 71 36 42 57 40 26 6 278
Regional nodal metastasis 106 81 16 18 59 42 18 340
Distant soft tissue / nodal
metastasis
37 26 13 11 11 9 11 118
Distant bone metastasis 207 169 42 50 132 91 41 732
Distant visceral metastasis 260 242 80 119 177 177 99 1154
Second breast cancer primary 48 89 30 108 22 42 7 346
Death without recurrence 10 76 7 102 9 14 5 223
Unknown 1 11 2 2 0 1 1 18
Total 1475 1212 1109 1669 1246 969 344 8024
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Appendix 3
Abbreviations
CI: Confidence interval; DFS: Disease-free survival; HR: Hazard ratio;
IBCSG: International Breast Cancer Study Group; LASA: Linear analog self-
assessment; OS: Overall survival; QL: Quality-of-life
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QL indictors N HR 95% CI N HR 95% CI
1 month before documented relapse
Physical well-being 199 1.004 0.997 1.010 136 1.003 0.996 1.011
Mood 199 1.001 0.994 1.007 136 0.999 0.992 1.006
Nausea / Vomiting 140 0.999 0.988 1.010 96 0.999 0.985 1.014
Appetite 199 1.002 0.995 1.009 136 1.000 0.992 1.009
Flushing 139 1.000 0.994 1.007 96 1.002 0.994 1.010
Arm swelling 139 1.005 0.997 1.014 95 1.010 1.000 1.020
Coping 198 1.000 0.994 1.005 135 1.000 0.993 1.006
Utility 138 0.998 0.989 1.007 94 0.998 0.987 1.008
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Physical well-being 163 1.005 0.998 1.011 117 1.003 0.995 1.010
Mood 162 1.008 1.001 1.015 117 1.008 1.000 1.016
Nausea / Vomiting 90 0.994 0.983 1.005 66 0.993 0.981 1.005
Appetite 163 0.998 0.989 1.008 117 1.001 0.991 1.012
Flushing 90 1.003 0.995 1.010 66 1.003 0.994 1.011
Arm swelling 89 0.998 0.988 1.009 66 0.994 0.981 1.008
Coping 162 1.003 0.997 1.009 117 1.004 0.997 1.012
Utility 89 0.995 0.986 1.005 66 0.998 0.986 1.011
3 months before documented relapse
Physical well-being 315 0.996 0.991 1.002 189 0.994 0.988 1.001
Mood 315 0.999 0.994 1.004 189 0.997 0.991 1.003
Nausea / Vomiting 143 1.000 0.992 1.009 89 1.002 0.991 1.013
Appetite 313 0.999 0.993 1.005 187 0.998 0.990 1.006
Flushing 144 1.000 0.994 1.005 90 1.000 0.993 1.007
Arm swelling 144 0.998 0.991 1.004 90 0.998 0.991 1.005
Coping 309 0.998 0.994 1.003 184 0.996 0.990 1.002
Utility 142 0.996 0.989 1.004 88 0.995 0.986 1.005
QL quality-of-life, HR hazard ratio, CI confidence interval
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